Evidence for the participation of anti-ribosomal P antibodies in lupus nephritis

Reichlin, Morris; Wolfson‐Reichlin, Marianne

doi:10.1002/1529-0131(199912)42:12<2728::aid-anr34>3.0.co;2-m

Cited by 41 publications

(27 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present patient, anti-P may have clustered with LAC, and these two autoantibodies may have participated together to bring about renal lesions unrelated to the anti-DNA titers. Furthermore, pathogenetic potentials of anti-P in LN have been reported (29,30). Recently it has been reported that anti-p2GPI antibody as well as LACis closely related with thromboembolic events in patient with APS (3 1, 32).…”

Section: Discussionmentioning

confidence: 99%

An Anti-nuclear Antibody-negative Patient with Systemic Lupus Erythematosus (SLE) Accompanied with Anti-ribosomal P Antibody (anti-P).

et al. 2002

View full text Add to dashboard Cite

Wereport a case of an anti-nuclear antibody (ANA)-negative patient with systemic lupus erythematosus (SLE) accompanied with anti-phospholipid antibody syndrome (APS) and lupus nephritis (LN). Histological examination of placenta obtained by an artificially-induced abortion revealed multiple thromboses in the placental villi. Histology of biopsied kidney tissue revealed minimal change with deposits of immunoglobulinand complement. Anti-ribosomal P antibodies (anti-P) and lupus anticoagulant (LAC) were positive and anti-double stranded DNAantibody (anti-DNA)showed only a slightly positive titer in her serum. The intensity of proteinuria of the patient was correlated with the anti-P, but not anti-DNA titers.

show abstract

Section: Discussionmentioning

confidence: 99%

An Anti-nuclear Antibody-negative Patient with Systemic Lupus Erythematosus (SLE) Accompanied with Anti-ribosomal P Antibody (anti-P).

et al. 2002

View full text Add to dashboard Cite

show abstract

“…The antigenic analytes employed in these tests included purified native proteins, recombinant polypeptides, a synthetic peptide comprising the 22 C-terminal amino acids (C22), and a multiple antigen peptide construct (1,12,13,21,22,23,26,30,38). Recently, a Rib-P profile assay based on the three recombinant ribosomal P proteins and the C22 peptide in separate tests was developed and evaluated (22).Anti-Rib-P antibodies were mainly detected in patients during the active phase of SLE and were believed to be correlated with lupus nephritis or hepatitis (4,11,12,24,28,30,36). …”

mentioning

confidence: 99%

“…Anti-Rib-P antibodies were mainly detected in patients during the active phase of SLE and were believed to be correlated with lupus nephritis or hepatitis (4,11,12,24,28,30,36).…”

mentioning

confidence: 99%

“…Despite substantial investigations, the relationship between antiribosomal antibodies and organic central nervous system involvement is still controversial (4,5,11,12,15,19,23,25,29,31). Anti-Rib-P antibodies have also been reported to be correlated with lupus nephritis (24,28). Reasons for the discrepancy between correlation studies may be the difference in the criteria used to define and detect various disease features or the demographics and/or makeup of the patient cohorts being investigated.…”

mentioning

confidence: 99%

See 1 more Smart Citation

International Multicenter Evaluation of Autoantibodies to Ribosomal P Proteins

Mähler

Kessenbrock

Szmyrka

et al. 2006

Clin Vaccine Immunol

View full text Add to dashboard Cite

Autoantibodies to the ribosomal phosphoproteins (Rib-P) are a serological feature of patients with systemic lupus erythematosus (SLE). The reported prevalence of anti-Rib-P antibodies in SLE ranges from 10 to 40%, being higher in Asian patients. The variation in the observed frequency may be related to a number of factors but is dependent in large part on the test system used to detect the autoantibodies. An association of anti-Rib-P with central nervous system involvement and neuropsychiatric manifestations of SLE has been controversial. In the present international multicenter study, we evaluated the clinical accuracy of a new sensitive Rib-Pspecific enzyme-linked immunosorbent assay based on recombinant Rib-P polypeptides. The results showed that 21.3% of 947 SLE patients, but only 0.7% of 1,113 control patients, had a positive test result (P < 0.0001). The sensitivity, specificity, positive and negative predictive values, and diagnostic efficiency were determined to be 21.3%, 99.3%, 95.6%, 62.2%, and 65.3%, respectively. When evaluated in the context of participating centers, the prevalence of anti-Rib-P antibodies was found in descending frequency, as follows: China (35%) > Poland (34%) > Japan (28%) > United States (26%) > Germany (Freiburg; 23.3%) > Denmark (20.5%) > Germany (Berlin; 19%) > Mexico (15.7%) > Israel (11.7%) > Brazil (10%) > Canada (8%). The substantial data from this study indicate that the prevalence of anti-Rib-P antibodies may not be restricted to the genetic background of the patients or to the detection system but may depend on regional practice differences and patient selection. We confirm previously reported associations of antiribosomal antibodies with clinical symptoms and serological findings. Remarkably, we found a lower occurrence of serositis in Rib-P-positive lupus patients.Autoantibodies to the ribosomal phosphoproteins (Rib-P) are a serological feature of patients with systemic lupus erythematosus (SLE) (4,8,9). The Rib-P autoantigen(s) consists of three protein components of the 60S ribosomal subunit, designated P0 (38 kDa), P1 (19 kDa), and P2 (17 kDa) (8, 12). A pentameric complex composed of one copy of P0 and two copies each of P1 and P2 interacts with the 28S rRNA molecule to form a GTPase domain, which is active during the elongation step of protein translation (8). The major immunoreactive epitope of this ribosomal autoantigen has been localized to the carboxy-terminal domain, which is highly conserved in all three proteins and contains two phosphorylated serine residues (e.g., Ser 102 and Ser 105 of human P2) (8,16,17). Several studies have shown that both the acidic and hydrophobic clusters, but not the phosphorylation of the P proteins, are critical for autoantibody binding (8,16,23). Furthermore, epitope mapping studies have shown that the major epitope domain is located within the last six C-terminal amino acids (GFGLFD) (8,16,23).The reported prevalence of anti-Rib-P antibodies in SLE ranges from 10 to 40%, being higher in Asian patients and at a relatively low...

show abstract

“…Of note, it has also been disclosed that lupus nephritis is much more prevalent in antiribosomal P antibody-positive systemic lupus erythematosus (SLE) patients than in antiribosomal P antibody-negative ones [6,7]. Moreover, recent studies have also suggested the direct participation of antiribosomal P antibody in the pathogenesis of lupus nephritis [8]. In the present report, we describe a case of SSc complicated with the nephrotic syndrome due to glomerulonephritis which also showed elevation of serum antiribosomal P antibody, providing additional evidence for the involvement of this autoantibody in the development of glomerulonephritis.…”

Section: Introductionmentioning

confidence: 99%

Systemic sclerosis complicated with nephrotic syndrome: relevance with antiribosomal P antibody

Hirohata

Ohse

Takeuchi

et al. 2001

Rheumatology International

View full text Add to dashboard Cite

The nephrotic syndrome is an extremely rare occurrence in systemic sclerosis (SSc). Here we describe a 39-year-old woman with SSc who developed the nephrotic syndrome along with the expression of antiribosomal P antibody but not of anti-double-stranded DNA antibody in her serum. Although a renal biopsy specimen showed minimal changes on light microscopy, immunofluorescence studies showed granular deposition of C3 and IgM in the glomeruli. The patient recovered from the nephrotic syndrome with the decrease in serum antiribosomal P antibody after the daily administration of 60 mg of prednisolone. It is strongly suggested that antiribosomal P antibody might have been involved in the development of the nephrotic syndrome in our patient.

show abstract

Evidence for the participation of anti-ribosomal P antibodies in lupus nephritis

Cited by 41 publications

References 9 publications

An Anti-nuclear Antibody-negative Patient with Systemic Lupus Erythematosus (SLE) Accompanied with Anti-ribosomal P Antibody (anti-P).

An Anti-nuclear Antibody-negative Patient with Systemic Lupus Erythematosus (SLE) Accompanied with Anti-ribosomal P Antibody (anti-P).

International Multicenter Evaluation of Autoantibodies to Ribosomal P Proteins

Systemic sclerosis complicated with nephrotic syndrome: relevance with antiribosomal P antibody

Contact Info

Product

Resources

About